- Home
- ACET vs THTX Comparison
ACET vs THTX Comparison
Compare ACET & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- THTX
- Stock Information
- Founded
- ACET 1947
- THTX 1993
- Country
- ACET United States
- THTX Canada
- Employees
- ACET N/A
- THTX N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- ACET Health Care
- THTX Health Care
- Exchange
- ACET Nasdaq
- THTX Nasdaq
- Market Cap
- ACET 83.2M
- THTX 71.3M
- IPO Year
- ACET N/A
- THTX N/A
- Fundamental
- Price
- ACET $0.89
- THTX $1.55
- Analyst Decision
- ACET Buy
- THTX Hold
- Analyst Count
- ACET 6
- THTX 1
- Target Price
- ACET $6.00
- THTX N/A
- AVG Volume (30 Days)
- ACET 414.2K
- THTX 136.3K
- Earning Date
- ACET 03-06-2025
- THTX 04-09-2025
- Dividend Yield
- ACET N/A
- THTX N/A
- EPS Growth
- ACET N/A
- THTX N/A
- EPS
- ACET N/A
- THTX N/A
- Revenue
- ACET N/A
- THTX $85,866,000.00
- Revenue This Year
- ACET N/A
- THTX $3.57
- Revenue Next Year
- ACET N/A
- THTX $7.73
- P/E Ratio
- ACET N/A
- THTX N/A
- Revenue Growth
- ACET N/A
- THTX 5.02
- 52 Week Low
- ACET $0.74
- THTX $1.08
- 52 Week High
- ACET $2.43
- THTX $2.18
- Technical
- Relative Strength Index (RSI)
- ACET 55.27
- THTX 44.24
- Support Level
- ACET $0.74
- THTX $1.50
- Resistance Level
- ACET $0.81
- THTX $1.63
- Average True Range (ATR)
- ACET 0.06
- THTX 0.08
- MACD
- ACET 0.01
- THTX -0.00
- Stochastic Oscillator
- ACET 71.29
- THTX 43.48
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.